Dosing begins in trial of drug combo for severe fatty liver disease
The first healthy volunteers have been dosed in a Phase 1 clinical trial testing a combination therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form…
The first healthy volunteers have been dosed in a Phase 1 clinical trial testing a combination therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form…
A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…
A three-year program in Oregon is receiving a $7.5-million federal grant to improve healthcare for rural residents who use recreational drugs. The program will use…
Aramchol, a small molecule in the Galmed Pharmaceuticals pipeline, prevented and reversed inflammation and scarring (fibrosis) of the bile ducts in mouse models of…
The American Liver Foundation (ALF) is launching a first-of-its kind national database, called the ALF Living Donor Network, to connect people willing to…
A combination of pemafibrate and telmisartan, two medications approved in some countries to help manage cardiovascular conditions, may help reduce the buildup of liver fat…
October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…
Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us…
Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…
Supporters are gearing up for the 7th Annual PFIC Awareness Day on Oct. 5, with advocates behind the yearly event focused on improving public awareness,…